Company intelligence / Profile preview

Movetis

Turnhout, Antwerp Province, Belgiumeustartup.news ↗

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

Movetis developed Resolor (prucalopride), approved in Europe for chronic constipation. The company advanced several other compounds targeting GI diseases into clinical development, with M0002 reaching Phase IIb for ascites and others in earlier stages. Academic collaborations supported pipeline innovation. The company was acquired by Shire in late 2010.

Therapeutic areas: Gastroenterology
Modalities: Small molecules (notably prucalopride, a selective serotonin 5‑HT4 receptor agonist)
Industry: Biotech

Drug pipeline

3 assets

prucalopride

Commercial

Indications: Chronic constipation

2 more assets in the full pipeline.

Request access →

Partnerships

Academic partnerships with universities of Ghent, Leuven, Rotterdam

Beyond the preview

Go deeper on Movetis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Movetis.

Explore the full profile